AI summary · may contain errors
In a specialist IBS clinic in Leeds, UK, Rome V criteria for IBS showed 66·1% sensitivity and 80·1% specificity, with a positive likelihood ratio of 3·33.
- Open access
- 11 cites
Elsevier BV · Gastroenterology & Hepatology · ISSN 2468-1253
Rebuilt
AI summary · may contain errors
In a specialist IBS clinic in Leeds, UK, Rome V criteria for IBS showed 66·1% sensitivity and 80·1% specificity, with a positive likelihood ratio of 3·33.
AI summary · may contain errors
In adults with metabolic dysfunction-associated steatohepatitis and F2–F4c fibrosis, zalfermin 30 mg plus semaglutide 2·4 mg did not significantly improve NASH CRN fibrosis by week 52 versus placebo (24% vs 16%).
Newest first · last 60 days
AI summary · may contain errors
Robotic pancreatoduodenectomy is linked to similar major complications (34% vs 32%) but a faster median functional recovery by 2 days versus open surgery in 4 RCTs.
AI summary · may contain errors
In biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) with F2–F3 fibrosis, weekly pemvidutide reduced liver fat by -45·2% (1·2 mg) and -54·7% (1·8 mg) at week 48 versus -8·2% with placebo.
AI summary · may contain errors
Gallbladder and biliary diseases increased globally from 1990 to 2023, with prevalence rising to 264.4 million and DALYs to 8.2 million despite declining age-standardised rates.
AI summary · may contain errors
In non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (MASH), ALG-055009 reduced MRI-PDFF liver fat by placebo-adjusted -33·2% at 0·7 mg and -31·6% at 0·9 mg by week 12.
AI summary · may contain errors
In the UK PROFILE trial of adults with newly diagnosed Crohn’s disease, top-down infliximab plus immunomodulator reduced 5-year Crohn’s-related abdominal surgery (6 vs 28).
AI summary · may contain errors
In unselected colorectal cancer patients, multigene germline panel testing detects any pathogenic or likely pathogenic variant in 15·2% (95% CI 12·8–18·1; 1061/6925).
AI summary · may contain errors
On-demand TACE plus atezolizumab and bevacizumab improved investigator-assessed TACE-PFS to 11·30 months versus 7·03 months with on-demand TACE alone in unresectable intermediate-to-high HCC.
AI summary · may contain errors
In east and southeast Asia, inflammatory bowel disease is progressing through four epidemiological stages, with many countries currently in stage 2 where incidence acceleration is compounding prevalence.
AI summary · may contain errors
IBS lacks a definitive biomarker, yet three decades of research have linked peripheral and central abnormalities—including abnormal bile acid metabolism and accelerated colonic transit—to IBS symptoms via the gut-brain axis.
AI summary · may contain errors
STRIDE-III updates treat-to-target recommendations for Crohn’s disease and ulcerative colitis, defining 3 target categories and consensus thresholds, including new faecal calprotectin ranges.
AI summary · may contain errors
Simedeutirom, a thyroid hormone receptor-β agonist, achieved MASH improvement without fibrosis worsening in 37% of 80 mg and 30% of 160 mg patients at week 52.
Journals this month
Topics moving, week to 18 Nov 2026
By field